Clinical Trials Directory

Trials / Completed

CompletedNCT00605826

A Randomized, Blinded, Multicenter Study to Evaluate NASHA/Dx for the Treatment of Fecal Incontinence

A Randomized, Subject and Evaluator Blinded, Sham Controlled, Multicenter Study to Evaluate Efficacy and Safety of NASHA/Dx for the Treatment of Fecal Incontinence

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
206 (actual)
Sponsor
Bausch Health Americas, Inc. · Industry
Sex
All
Age
18 Years – 75 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to determine the effectiveness and safety of NASHA/Dx when used as an injectable bulking agent in the treatment of fecal incontinence. The study includes a 6-month blinded sham-controlled phase, followed by an open-label phase.

Detailed description

Subjects will be given up to 2 treatments of NASHA/Dx or sham and followed for 6 months from last treatment (ie, one retreatment is permitted at 1 month after the first injection) in the blinded phase of the study. At Month 6, the open phase of the study will begin and subjects on sham will be offered open-label treatment with NASHA/Dx. Subjects who receive NASHA/Dx at the start of the blinded phase will be followed for up to 36 months from last treatment in the blinded phase. Subjects who receive sham at the start of the blinded phase and then receive open-label NASHA/Dx at Month 6 (start of the open phase) will be followed for another 24 months (equivalent to approximately 30 months from randomization) from last treatment in the open phase of the study.

Conditions

Interventions

TypeNameDescription
DEVICENASHA/Dx (Solesta) GelInjection of 4 x 1ml of NASHA/Dx Gel at the start of the blinded phase.
DEVICESham InjectionSham injection at the start of the blinded phase.

Timeline

Start date
2006-09-07
Primary completion
2009-11-23
Completion
2009-11-23
First posted
2008-01-31
Last updated
2020-08-18
Results posted
2020-08-18

Locations

13 sites across 4 countries: United States, Germany, Sweden, United Kingdom

Source: ClinicalTrials.gov record NCT00605826. Inclusion in this directory is not an endorsement.